European CDMO Market for Plasmids, Recombinant Proteins and Antibodies

CHALLENGE

A leading European private equity firm sought to gain in-depth insights into the recombinant proteins, antibodies, and plasmid markets, focusing particularly on the CDMO (Contract Development and Manufacturing Organization) sector in Europe. Their objective was to understand the market dynamics, technical intricacies, and business opportunities in these segments, especially in relation to plasmid production.

BTHT APPROACH

BTHT implemented a multi-faceted research strategy aimed at identifying and engaging top-tier experts with comprehensive knowledge and experience in the relevant fields. Our approach involved targeting professionals with proven expertise in recombinant proteins, antibodies, and plasmid production from both pharma and CDMO perspectives. Our team sourced:

• R&D Directors with deep technical knowledge in plasmid production and related biotechnologies.
• Business Development Directors who understand market trends and business strategies in the CDMO sector.
• Global Operational Excellence Vice President to provide insights on optimizing production processes and operational efficiency.
• Chief Technical Officers with a holistic view of technical and strategic aspects in biotech production.
• Global Program Development Leaders with experience in leading large-scale projects in the pharmaceutical and biotech industries.

BTHT facilitated 1 hour consultations between the client and the selected experts, ensuring discussions were focused and productive, and that they were conducted without any technical issue.

OUTCOME

Through BTHT's targeted and strategic approach, the private equity firm was able to gain comprehensive insights into the European recombinant proteins, antibodies, and plasmid markets from both pharma and CDMO perspectives. The experts provided detailed information on market dynamics, technical challenges, and opportunities, as well as strategic advice on navigating the market. This enabled the client to make better investment decisions, optimize their strategic planning, and identify key areas for growth and development in the biotech sector.